Table 5A.
Network meta-analysis of the efficacy of UPDRSIII.
| SP-HI-RT | NA | NA | NA | NA | NA | NA | −0.95 (−1.68; −0.22) | NA |
| −0.51 (−1.48; 0.45) | LP-MI-AE | −0.21 (−1.04; 0.62) | NA | NA | NA | NA | −0.26 (−1.09; 0.57) | NA |
| −0.54 (−1.41; 0.32) | −0.03 (−0.66; 0.60) | LP-HI-AE | NA | NA | −1.28 (−2.74; 0.18) | NA | −0.36 (−0.90; 0.17) | NA |
| −0.54 (−1.94; 0.86) | −0.03 (−1.38; 1.32) | −0.00 (−1.28; 1.28) | SP-MI-AE | NA | NA | NA | −0.41 (−1.60; 0.78) | NA |
| −0.70 (−1.71; 0.32) | −0.18 (−1.13; 0.76) | −0.16 (−1.00; 0.69) | −0.16 (−1.54; 1.23) | SP-HI-AE | NA | NA | −0.31 (−1.10; 0.47) | −0.22 (−1.35; 0.91) |
| −0.90 (−1.81; 0.01) | −0.39 (−1.20; 0.43) | −0.36 (−1.03; 0.32) | −0.36 (−1.67; 0.96) | −0.20 (−1.09; 0.69) | LP-HI-RT | NA | −0.20 (−0.79; 0.38) | NA |
| −0.99 (−2.20; 0.21) | −0.48 (−1.63; 0.67) | −0.45 (−1.52; 0.62) | −0.45 (−1.98; 1.08) | −0.30 (−1.49; 0.90) | −0.09 (−1.20; 1.01) | LP-LI-AE | 0.04 (−0.92; 1.00) | NA |
| −0.44 (−1.07; 0.19) | −0.41 (−0.87; 0.05) | −0.41 (−1.60; 0.78) | −0.25 (−0.96; 0.45) | −0.05 (−0.60; 0.49) | 0.04 (−0.92; 1.00) | CON | −0.21 (−1.34; 0.91) | |
| −1.04 (−2.18; 0.10) | −0.53 (−1.60; 0.55) | −0.50 (−1.49; 0.49) | −0.50 (−1.98; 0.98) | −0.34 (−1.21; 0.53) | −0.14 (−1.17; 0.89) | −0.05 (−1.34; 1.25) | −0.09 (−0.96; 0.78) | SP-LI-RT |